Amicus Therapeutics Shares Outstanding 2007-2021 | FOLD
Amicus Therapeutics shares outstanding from 2007 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Amicus Therapeutics Annual Shares Outstanding
(Millions of Shares) |
| 2020 |
259 |
| 2019 |
240 |
| 2018 |
186 |
| 2017 |
153 |
| 2016 |
134 |
| 2015 |
110 |
| 2014 |
74 |
| 2013 |
51 |
| 2012 |
46 |
| 2011 |
35 |
| 2010 |
28 |
| 2009 |
23 |
| 2008 |
22 |
| 2007 |
13 |
| 2006 |
1 |
| 2005 |
0 |
Amicus Therapeutics Quarterly Shares Outstanding
(Millions of Shares) |
| 2021-06-30 |
266 |
| 2021-03-31 |
264 |
| 2020-12-31 |
259 |
| 2020-09-30 |
259 |
| 2020-06-30 |
258 |
| 2020-03-31 |
257 |
| 2019-12-31 |
240 |
| 2019-09-30 |
255 |
| 2019-06-30 |
238 |
| 2019-03-31 |
214 |
| 2018-12-31 |
186 |
| 2018-09-30 |
189 |
| 2018-06-30 |
189 |
| 2018-03-31 |
176 |
| 2017-12-31 |
153 |
| 2017-09-30 |
161 |
| 2017-06-30 |
143 |
| 2017-03-31 |
143 |
| 2016-12-31 |
134 |
| 2016-09-30 |
141 |
| 2016-06-30 |
129 |
| 2016-03-31 |
125 |
| 2015-12-31 |
110 |
| 2015-09-30 |
119 |
| 2015-06-30 |
100 |
| 2015-03-31 |
96 |
| 2014-12-31 |
74 |
| 2014-09-30 |
79 |
| 2014-06-30 |
67 |
| 2014-03-31 |
64 |
| 2013-12-31 |
51 |
| 2013-09-30 |
50 |
| 2013-06-30 |
50 |
| 2013-03-31 |
50 |
| 2012-12-31 |
46 |
| 2012-09-30 |
49 |
| 2012-06-30 |
47 |
| 2012-03-31 |
38 |
| 2011-12-31 |
35 |
| 2011-09-30 |
35 |
| 2011-06-30 |
35 |
| 2011-03-31 |
34 |
| 2010-12-31 |
28 |
| 2010-09-30 |
28 |
| 2010-06-30 |
28 |
| 2010-03-31 |
24 |
| 2009-12-31 |
23 |
| 2009-09-30 |
23 |
| 2009-06-30 |
23 |
| 2009-03-31 |
23 |
| 2008-12-31 |
22 |
| 2008-09-30 |
23 |
| 2008-06-30 |
22 |
| 2008-03-31 |
22 |
| 2007-12-31 |
13 |
| 2007-09-30 |
22 |
| 2007-06-30 |
7 |
| 2007-03-31 |
1 |
| 2006-09-30 |
1 |
| 2006-06-30 |
1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.959B |
$0.261B |
|
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
|
